You are here
Products
PD-L1/PDCD1-L1/CD274 [MD21R]
Product group: | Primary |
Monoclonal/ Polyclonal: | Monoclonal |
Clone: | MD21R |
Host: | Rabbit |
Isotype: | IgG |
Application: | Flow cytometry (FC), Immunofluorescence (IF), Immunohistochemistry (IHC), Immunoprecipitation (IP), Western Blot (WB) |
Application notes: | Prediluted |
Conjugation Type: | Unconjugated |
Reactivity: | Human |
General notes: | Localization: membrane, cytoplasm. |
Buffer: | EDTA pH8.0 |
UNSPSC code: | 12352203 |
Programmed cell death 1 ligand 1 (PD-L1) also known as CD274 or B7-H1, a member of the B7 family of cell surface ligands, involved in regulation of T cell activation and humoral immune responses. The PD-L1 binds its transmember receptor PD-1 and provides both stimulatory and inhibitory signals in regulating T cell activation and tolerance during pregnancy,tissue allografts, autoimmune disease and malignant transformation. PD-L1 is expressed in activated T and B cells, placenta and some tumors including melanoma, diffused large B-cell lymphoma, lung, ovary, colon, breast, rectum and renal cell carcinomas. Expression of PD-L1 in cancer is associated with tumor infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma. Additional research links PD-L1 expression to cancers associated with viral infections. (Shipping Cost: €200.00)
PD-L1/PDCD1-L1/CD274 [MD21R]
Programmed cell death 1 ligand 1 (PD-L1) also known as CD274 or B7-H1, a member of the B7 family of cell surface ligands, involved in regulation of T cell activation and humoral immune responses. The PD-L1 binds its transmember receptor PD-1 and provides both stimulatory and inhibitory signals in regulating T cell activation and tolerance during pregnancy,tissue allografts, autoimmune disease and malignant transformation. PD-L1 is expressed in activated T and B cells, placenta and some tumors including melanoma, diffused large B-cell lymphoma, lung, ovary, colon, breast, rectum and renal cell carcinomas. Expression of PD-L1 in cancer is associated with tumor infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma. Additional research links PD-L1 expression to cancers associated with viral infections.
Alternative names: